Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?
- 21 March 2013
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 15 (3) , 276-285
Abstract
Chemotherapy-induced nausea and vomiting is one of the most concerning adverse drug effects from cytotoxic chemotherapy. Despite appropriate use of antiemetic guidelines, 20–30 % of patients experience breakthrough nausea and vomiting secondary to chemotherapy. To assess the variability of 5-hydroxytryptamine type 3 receptor antagonist efficacy caused by genetic variation, a review of the available literature was conducted. From the literature, three sources of pharmacogenomic variability were identified: polymorphisms associated with 5-hydroxytryptamine type 3 receptor subunits, drug metabolism via cytochromes P450, and drug transport in the body. Testing for receptor subunit polymorphisms is not applicable to a clinical setting at this time; however, cytochrome P450 2D6 testing is FDA-approved and widely accessible. Cytochrome P450 2D6 ultrarapid metabolizers and poor metabolizers displayed altered antiemetic efficacy when compared with intermediate metabolizers and extensive metabolizers. We postulate that testing for cytochrome P450 2D6 phenotypes may be the most accessible way to provide individualized antiemetic therapy in the future.Keywords
This publication has 50 references indexed in Scilit:
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) GenotypeClinical Pharmacology & Therapeutics, 2011
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2011
- Serotonin receptor 3A polymorphism c.-42C > T is associated with severe dyspepsiaBMC Medical Genetics, 2011
- Therapeutics of 5-HT3 receptor antagonists: Current uses and future directionsPharmacology & Therapeutics, 2011
- Update and new trends in antiemetic therapy: the continuing need for novel therapiesAnnals of Oncology, 2010
- Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapyJournal of Cancer Research and Clinical Oncology, 2008
- The 5-HT3receptor as a therapeutic targetExpert Opinion on Therapeutic Targets, 2007
- PalonosetronDrugs, 2004
- The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicineSupportive Care in Cancer, 2001
- Consensus proposal for 5HT 3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapySupportive Care in Cancer, 1998